Patents by Inventor Orhan Soykan
Orhan Soykan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8003373Abstract: Activation of an enzyme in a bodily fluid is detected based on the amount of cleavage of a substrate for the enzyme. The substrate is tagged with two fluorescent dyes—a donor and an acceptor. The tagged substrate is presented to the bodily fluid. A device emits energy at a first wavelength into the bodily fluid, and detects energy at second and third wavelengths emitted by the dyes in response to the energy at the first wavelength. Prior to enzymatic cleavage of the substrate, the acceptor emits energy at the third wavelength in response to energy at the second wavelength received through fluorescent resonant energy transfer (FRET) from the donor. After enzymatic cleavage of the substrate, the donor emits energy at the second wavelength. The device can determine the concentration of activated enzyme within the bodily fluid based on the relative intensities of energy, at the second and third wavelengths.Type: GrantFiled: May 28, 2008Date of Patent: August 23, 2011Assignee: Medtronic, Inc.Inventors: Orhan Soykan, Maura G. Donovan
-
Publication number: 20110143956Abstract: Variations in certain genomic sequences useful as genetic markers of Sudden Cardiac Death (“SCD”) or Sudden Cardiac Arrest (“SCA”) risk are described. Novel diagnostic kits, DNA microarrays, and methods employing these genetic markers are used in assessing the risk of SCD or SCA. Methods of distinguishing patients having an increased susceptibility to SCD or SCA, through use of these markers, alone or in combination with other markers, are also provided. Further, methods of detecting a polymorphism associated with SCD or SCA are taught.Type: ApplicationFiled: December 7, 2010Publication date: June 16, 2011Applicant: MEDTRONIC, INC.Inventors: Orhan Soykan, Tara Nahey, Jeffrey Lande
-
Publication number: 20110143345Abstract: Variations in certain genomic sequences useful as genetic markers of Sudden Cardiac Death (“SCD”) or Sudden Cardiac Arrest (“SCA”) risk are described. Novel genetic markers useful in assessing the risk of SCD or SCA and compositions containing the same are provided herein. Methods of distinguishing patients having an increased susceptibility to SCD or SCA, through use of these markers, alone or in combination with other markers, are also provided. Further, methods of detecting a polymorphism associated with SCD or SCA are taught.Type: ApplicationFiled: December 7, 2010Publication date: June 16, 2011Applicant: MEDTRONIC, INC.Inventors: Orhan Soykan, Tara Nahey, Jeffrey Lande
-
Publication number: 20110071589Abstract: In some examples, the disclosure relates to a systems, devices, and techniques for delivering electrical stimulation therapy to a patient. In one example, the disclosure relates to a method including delivering a series of pulses with alternating pulse polarities to a gastrointestinal tract of a patient. The series of pulses includes at least a first pulse of a first polarity, a second pulse of a second polarity, and a third pulse of the first polarity, where the first, second and third pulses are delivered in direct succession and in that order. The first and second pulses are separated by a first time delay and the second and third pulses are separated by a second time delay. In some examples, each of the first and second time delays depend on the frequency that the series of pulses are delivered.Type: ApplicationFiled: September 21, 2010Publication date: March 24, 2011Applicant: Medtronic, Inc.Inventors: Warren L. Starkebaum, Roland C. Maude-Griffin, Elizabeth D. Firestone, Carl A. Schu, Orhan Soykan
-
Publication number: 20100317006Abstract: Genetic tests and methods for treatment based on markers to identify patients suffering from life-threatening ventricular tachy-arrhythmias, such as Ventricular Tachycardias (“VT”) and Ventricular Fibrillation (“VF”) that might lead to Sudden Cardiac Arrest (“SCA”) or Sudden Cardiac Death (“SCD”) are provided. Patients who cannot be sufficiently protected by medication alone, such as those refractory to anti-arrhythmic medication, are identified based on their genotype. The resulting information is used in a diagnostic test to identify and treat those patients who would benefit from the implantation of an Implantable Cardio Defibrillator (“ICD”).Type: ApplicationFiled: May 12, 2010Publication date: December 16, 2010Applicant: MEDTRONIC, INC.Inventors: Orhan SOYKAN, Tara NAHEY, Jeffrey LANDE
-
Patent number: 7778705Abstract: Heart pacing systems include at least one electronic or biological pacemaker as a primary pacemaker, and at least one electronic or biological pacemaker as a backup pacemaker. When implanted, the primary pacemaker(s) produce primary pacing stimuli that modulate cardiac function. The backup pacemaker(s) provide backup pacing stimuli when the electronic pacemaker is unable to modulate cardiac function at the predetermined pacing rate. The heart pacing systems are implemented by implantation in regions where they can provide pacing stimuli to cardiac tissue.Type: GrantFiled: October 31, 2006Date of Patent: August 17, 2010Assignee: Medtronic, Inc.Inventors: Daniel C. Sigg, Timothy G. Laske, Vinod Sharma, Orhan Soykan
-
Publication number: 20100098207Abstract: A method and device are described to form a heat producing plant with replaceable fusion-based reaction cartridges, where the fuel is embedded in casings in the preferred embodiment, and the heat can be converted into electrical or mechanical energy. The replaceable unit consists of sheets containing individual heating elements that are addressed sequentially to trigger the heat producing reactions. A controller governs the triggering activity until all the elements are used. The resulting heat can be converted into mechanical energy using turbines and into electrical energy using the Seebeck effect. This inventive device can be used in mobile environments as well as at fixed locations where heat, mechanical power or electricity are needed.Type: ApplicationFiled: October 16, 2009Publication date: April 22, 2010Inventor: Orhan Soykan
-
Publication number: 20100047915Abstract: The invention is a method for identifying proteins associated with sudden cardiac death (SCD) and for assessing a patient's risk of SCD by determining the amount of one or more SCD-associated proteins in the patient. Typically, the patient submits a sample, such as a blood sample, which is tested for one or more SCD-associated proteins. Based upon the results of the tests, the patient's risk of SCD may be assessed.Type: ApplicationFiled: October 26, 2009Publication date: February 25, 2010Applicant: MEDTRONIC, INC.Inventors: Orhan Soykan, Amy C. Dearking, Timothy H. Robinson, Walter H. Olson, Vinod Sharma
-
Patent number: 7647122Abstract: A needle driver is described that can be used to drive a plurality of surgical needles into or proximate to tissue of a living body. The needle driver assists the surgeon in perforating the tissue, creating the tracts at a desired depth, and creating multiple tracts simultaneously. The needle driver is configured to hold the needles securely when creating the tracts, and is also configured to disengage from the needles after the tracts have been created.Type: GrantFiled: July 26, 2005Date of Patent: January 12, 2010Assignee: Medtronic, Inc.Inventors: Cygni Chan, Carl A. Schu, Orhan Soykan, Terrell M. Williams
-
Patent number: 7622303Abstract: In general, the invention is directed to systems and techniques for assessing a risk of ventricular tachyarrhythmia in a patient by measuring one or more biochemical markers that reflect the health of a patient. Typically, the patient submits a sample, such as a blood sample, which is tested for one or more biomarkers. Based upon the results of the tests, the patient's risk of ventricular tachyarrhythmia may be assessed. When the patient is found to be at risk, the patient may receive an implantable medical device or drug therapy to address the risk.Type: GrantFiled: February 3, 2005Date of Patent: November 24, 2009Assignee: Medtronic, Inc.Inventors: Orhan Soykan, Timothy H. Robinson, Walter H. Olson, Vinod Sharma, Amy C. Dearking
-
Patent number: 7608458Abstract: The invention is a method for identifying proteins associated with sudden cardiac death (SCD) and for assessing a patient's risk of SCD by determining the amount of one or more SCD-associated proteins in the patient. Typically, the patient submits a sample, such as a blood sample, which is tested for one or more SCD-associated proteins. Based upon the results of the tests, the patient's risk of SCD may be assessed.Type: GrantFiled: June 21, 2005Date of Patent: October 27, 2009Assignee: Medtronic, Inc.Inventors: Orhan Soykan, Amy C. Dearking, Timothy H. Robinson, Walter H. Olson, Vinod Sharma
-
Publication number: 20090136954Abstract: Variations in certain genomic sequences useful as genetic markers of Sudden Cardiac Death (“SCD”), or Sudden Cardiac Arrest (“SCA”) risk, are described. Novel genetic markers useful in assessing the risk of SCD, or SCA, and kits containing the same are provided herein. Methods of distinguishing patients having an increased susceptibility to SCD, or SCA, through use of these markers, alone or in combination with other markers, are also provided. Further, methods of assessing the need for an Implantable Cardio Defibrillators (“ICD”) in a patient are taught.Type: ApplicationFiled: November 14, 2008Publication date: May 28, 2009Applicant: MEDTRONIC, INC.Inventors: Orhan SOYKAN, Tara NAHEY, Jeffrey LANDE
-
Publication number: 20090131276Abstract: Variations in certain genomic sequences useful as genetic markers of Sudden Cardiac Death (“SCD”), or Sudden Cardiac Arrest (“SCA”) risk, are described. Novel diagnostic kits and methods employing these genetic markers are used in assessing the risk of SCD, or SCA. Methods of distinguishing patients having an increased susceptibility to SCD, or SCA, through use of these markers, alone or in combination with other markers, are also provided. Further, methods of assessing the need for an Implantable Cardio Defibrillators (“ICD”) in a patient are taught.Type: ApplicationFiled: November 14, 2008Publication date: May 21, 2009Applicant: MEDTRONIC, INC.Inventors: Orhan SOYKAN, Tara NAHEY, Jeffrey LANDE
-
Patent number: 7473548Abstract: Activation of an enzyme in a bodily fluid is detected based on the amount of cleavage of a substrate for the enzyme. The substrate is tagged with two fluorescent dyes—a donor and an acceptor. The tagged substrate is presented to the bodily fluid. A device emits energy at a first wavelength into the bodily fluid, and detects energy at second and third wavelengths emitted by the dyes in response to the energy at the first wavelength. Prior to enzymatic cleavage of the substrate, the acceptor emits energy at the third wavelength in response to energy at the second wavelength received through fluorescent resonant energy transfer (FRET) from the donor. After enzymatic cleavage of the substrate, the donor emits energy at the second wavelength. The device can determine the concentration of activated enzyme within the bodily fluid based on the relative intensities of energy at the second and third wavelengths.Type: GrantFiled: April 25, 2003Date of Patent: January 6, 2009Assignee: Medtronic, Inc.Inventors: Orhan Soykan, Maura G. Donovan, Amy E. Thompson
-
Publication number: 20080227083Abstract: Activation of an enzyme in a bodily fluid is detected based on the amount of cleavage of a substrate for the enzyme. The substrate is tagged with two fluorescent dyes—a donor and an acceptor. The tagged substrate is presented to the bodily fluid. A device emits energy at a first wavelength into the bodily fluid, and detects energy at second and third wavelengths emitted by the dyes in response to the energy at the first wavelength. Prior to enzymatic cleavage of the substrate, the acceptor emits energy at the third wavelength in response to energy at the second wavelength received through fluorescent resonant energy transfer (FRET) from the donor. After enzymatic cleavage of the substrate, the donor emits energy at the second wavelength. The device can determine the concentration of activated enzyme within the bodily fluid based on the relative intensities of energy, at the second and third wavelengths.Type: ApplicationFiled: May 28, 2008Publication date: September 18, 2008Inventors: Orhan Soykan, Maura G. Donovan
-
Publication number: 20080103537Abstract: Heart pacing systems include at least one electronic or biological pacemaker as a primary pacemaker, and at least one electronic or biological pacemaker as a backup pacemaker. When implanted, the primary pacemaker(s) produce primary pacing stimuli that modulate cardiac function. The backup pacemaker(s) provide backup pacing stimuli when the electronic pacemaker is unable to modulate cardiac function at the predetermined pacing rate. The heart pacing systems are implemented by implantation in regions where they can provide pacing stimuli to cardiac tissue.Type: ApplicationFiled: October 31, 2006Publication date: May 1, 2008Inventors: Daniel C. Sigg, Timothy G. Laske, Vinod Sharma, Orhan Soykan
-
Patent number: 7349740Abstract: In general, the invention is directed to methods for electrically stimulating transplanted biological material, such as transplanted cells, to improve the performance of the heart during systole. In particular, the invention is directed to devices and techniques for stimulating biological material transplanted in a myocardium of a heart during an ejection phase of a cardiac cycle. The transplanted biological material may include cells, such as skeletal myoblasts, precursor cells, endothelial cells, differentiated or undifferentiated stem cells, undifferentiated contractile cells, fibroblasts and genetically engineered cells. In general, stimulation of the transplanted biological material during the ejection phase of the cardiac cycle, when the aortic and pulmonary valves are open, provides hemodynamic assistance to the heart.Type: GrantFiled: July 22, 2004Date of Patent: March 25, 2008Assignee: Medtronic, Inc.Inventors: Orhan Soykan, Donovan G. Maura
-
Patent number: 7310545Abstract: A method and device are described to form a sensor using a cardiomyocyte by advancing a catheter into the tissue of interest, cardiac in the preferred embodiment, and using the catheter to ablate a cone- or a dome-shaped region to form an electrically isolated section of tissue. An electrode is later fixed to the region encompassed by the dome-shaped area of tissue and used to detect the electrophysiological activity of this electrically independent cluster of cells. These cells combined with the electrode and a detection circuitry will form a cell-based sensor to monitor the effects of the anti-arrhythmic drugs in the circulation. The inventive device includes an ablation catheter and a sensing lead. Catheter is a hollow conductor which used to carry RF power from the external generator to the myocardium and to form a cone-shaped ablation zone to electrically isolate a part of myocardium from the rest.Type: GrantFiled: April 8, 2003Date of Patent: December 18, 2007Assignee: Medtronic, Inc.Inventor: Orhan Soykan
-
Publication number: 20070106201Abstract: An implantable system is provided that includes: a cell repopulation source comprising genetic material, undifferentiated and/or differentiated contractile cells, or a combination thereof capable of forming new contractile tissue in and/or near an infarct zone of a patient's myocardium; and an electrical stimulation device for electrically stimulating the new contractile tissue in and/or near the infarct zone of the patient's myocardium or otherwise damaged or diseased myocardial tissue.Type: ApplicationFiled: November 18, 2006Publication date: May 10, 2007Inventors: Orhan Soykan, Maura Donovan
-
Publication number: 20070027512Abstract: A stimulation electrode array is described. The electrode array can include multiple electrode sets, and can be connected by a single lead to an implantable pulse generator. The implantable pulse generator can drive one set of electrodes to one potential, and another set to a different potential. When implanted in target tissue, the electrodes can stimulate the target tissue while avoiding stimulation of neighboring muscles, organs or nerves.Type: ApplicationFiled: July 26, 2005Publication date: February 1, 2007Applicant: Medtronic, Inc.Inventors: Cygni Chan, Carl Schu, Orhan Soykan, Terrell Williams